Catalyst overview
Research summary
This catalyst tracks a Approved update for Orforglipron in Obesity. The expected timing is based on the latest available company guidance and may change.
ATTAIN-1/2 program. 6/26/23- Trial initiated. 8/26/25- Met primary & secondary endpoints. Submit to global regulatory agencies for approval by YE 2025. 02/26/26:- FDA obesity decision for orforglipron expected in Q2 2026 after global submissions. 04/01/26:- FDA approved Foundayo (orforglipron) for obesity/overweight. LillyDirect shipping begins April 6. 04/09/26:- Foundayo now ships nationwide via LillyDirect and retail pharmacies; Medicare Part D $50/month begins July 1, 2026. 05/12/26:- ATTAIN-MAINTAIN Phase 3b detailed results met endpoints for Foundayo weight maintenance. 05/28/26:- ATTAIN-1/2 menopause subgroup analyses to be presented at ADA June 5-8, 2026.
Verification
Confirm timing and program details against the company announcement or filing.